Tag: Xeltis

Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023

Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023 aXess demonstrated exceptional patency rates and no infections to date EINDHOVEN, The Netherlands – 17 November 2023, Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces […]

Xeltis secures additional €12.5 million from European Innovation Council Fund in final close of D2 financing

EINDHOVEN, The Netherlands – 14 August 2023, Xeltis a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels today announces the closing of an additional €12.5 million in funding from the European Innovation Council (EIC) Fund, set up by the European Commission. Today’s extension […]

Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress

Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress aXess graft demonstrated excellent patency, low rates of infection and re-intervention Data indicates a significant improvement in performance compared to standard hemodialysis access treatment EINDHOVEN, The Netherlands – 28 April 2023, Xeltis, a developer of transformative implants that enable the natural creation of living […]

Xeltis Initiates First-ever Pivotal Trial of a Synthetic Restorative Pulmonary Heart Valve

Patient’s own tissue naturally turn device into living heart valves and may reduce need for re-interventions EINDHOVEN, the Netherlands & ZURICH–(BUSINESS WIRE)–Xeltis, a clinical-stage company with the most advanced polymer-based restorative cardiovascular devices, today announced that it has started the first-ever pivotal trial for a synthetic restorative pulmonary valve. To […]

Xeltis Closes $52M for Replacement Heart Valve Programs

EINDHOVEN, The Netherlands and ZURICH, November 15, 2017 /PRNewswire/ — Xeltis, a clinical-stage medical device company pioneering a restorative approach in heart valve therapy, today announced the completion of an oversubscribed EUR45 million ($52 million) Series C financing. The funding round was led by a global strategic investor with participation […]